{"organizations": [], "uuid": "88fe73b7600a33720b85f83e7d97526b3f495a4b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-moodys-says-87-bln-acquisition-of/brief-moodys-says-8-7-bln-acquisition-of-avexis-strengthens-novartiss-pipeline-in-gene-therapy-idUSFWN1RN0B8", "country": "US", "domain_rank": 408, "title": "BRIEF-Moody's Says $8.7 bln Acquisition Of Avexis Strengthens Novartis's Pipeline In Gene Therapy", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-10T11:24:00.000+03:00", "replies_count": 0, "uuid": "88fe73b7600a33720b85f83e7d97526b3f495a4b"}, "author": "", "url": "https://www.reuters.com/article/brief-moodys-says-87-bln-acquisition-of/brief-moodys-says-8-7-bln-acquisition-of-avexis-strengthens-novartiss-pipeline-in-gene-therapy-idUSFWN1RN0B8", "ord_in_thread": 0, "title": "BRIEF-Moody's Says $8.7 bln Acquisition Of Avexis Strengthens Novartis's Pipeline In Gene Therapy", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "novartis", "sentiment": "negative"}, {"name": "moody’s", "sentiment": "none"}, {"name": "moody", "sentiment": "none"}, {"name": "pipeline in gene therapy reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 10, 2018 / 8:27 AM / Updated 12 minutes ago BRIEF-Moody's Says $8.7 bln Acquisition Of Avexis Strengthens Novartis's Pipeline In Gene Therapy Reuters Staff 1 Min Read \n  Moody’s: \n* MOODY’S SAYS $8.7 BILLION ACQUISITION OF AVEXIS STRENGTHENS NOVARTIS’S PIPELINE IN GENE THERAPY, BUT REDUCES FINANCIAL FLEXIBILITY \n* MOODY’S SAYS MONETISING VALUE OF JV STAKE HAS REDUCED DIVERSITY BUT INCREASED CASH BALANCES, AND LEFT UNCERTAINTY OVER USE OF PROCEEDS \n* MOODY’S SAYS EXPECT THAT AVXS-101, IF APPROVED, WILL ONLY HAVE A MEANINGFUL IMPACT ON NOVARTIS’S EBITDA AND CREDIT METRICS FROM 2020 ONWARDS \n* MOODY'S SAYS DEAL WILL NOT DO MUCH TO IMPROVE NOVARTIS'S CREDIT METRICS OVER NEXT 2 YEARS AND WE EXPECT COMPANY TO CONTINUE OPERATING WITH A LEVERAGE Source: bit.ly/2HegzGl Further company coverage:", "external_links": [], "published": "2018-04-10T11:24:00.000+03:00", "crawled": "2018-04-10T11:38:52.016+03:00", "highlightTitle": ""}